Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Beam Therapeutics BEAM and Intellia Therapeutics NTLA are clinical-stage companies developing investigational gene therapies.

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. Lilly ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research and Evaluation (CBER) faced another abrupt leadership transition following ...

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Cibus, Inc., a leading agricultural biotechnology firm, announced that Co-Founder and Interim CEO Peter Beetham will present at the AGP Annual Virtual Healthcare Company Showcase on May 21, 2025. He ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike to ...